Clinical Outcomes of Patients With Metastatic NSCLC After Discontinuation of Immunotherapy Because of Immune-Related Adverse Effects

Clinical Outcomes of Patients With Metastatic NSCLC After Discontinuation of Immunotherapy Because of Immune-Related Adverse Effects

Introduction: Immune checkpoint inhibition (ICI) is an important treatment modality in metastatic NSCLC and management of immunotherapy-related adverse effects (irAEs) can be challenging. Retreatment after discontinuation of ICI because of irAEs is a frequent clinical dilemma with limited available...

Full description

Bibliographic Details
Main Authors: Lysanne A. Lievense, MD, PhD, Peter Heukels, MD, PhD, Nico C. van Walree, MD, Cor H. van der Leest, MD, PhD
Format: Article
Language:English
Published: Elsevier 2023-01-01
Series:JTO Clinical and Research Reports
Subjects:
Non–small cell lung cancer
Immunotherapy
Immune-related adverse effects
Clinical outcomes
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364322001655

Internet

http://www.sciencedirect.com/science/article/pii/S2666364322001655

Similar Items